SHH inhibitors for the treatment of medulloblastoma

Expert Review of Neurotherapeutics

Volumn 15, Issue 7, 2015, Pages 763-770

  Samkari, Ayman ^a,b   White, Jason ^a   Packer, Roger ^c,d  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b ST CHRISTOPHER'S HOSPITAL FOR CHILDREN   (United States)

^c GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

basal cell carcinoma; gorlin syndrome; medulloblastoma; smoothened; sonic hedghog; vismodegib

Indexed keywords

6 ETHYL 4,5 DIHYDRO N [1 (HYDROXYACETYL) 4 PIPERIDINYL] 1 METHYL 4 OXO 5 (2 OXO 2 PHENYLETHYL) 3 (2,2,2 TRIFLUOROETHOXY) 1H PYRROLO[3,2 C]PYRIDINE 2 CARBOXAMIDE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BMS 833923; BROMODOMAIN INHIBITOR; CYCLOPAMINE; FORETINIB; GLASDEGIB; ITRACONAZOLE; MEBENDAZOLE; PATIDEGIB; PEMETREXED; PF 5274857; PYRIDINE DERIVATIVE; SONIC HEDGEHOG INHIBITOR; SONIC HEDGEHOG PROTEIN; SONIDEGIB; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VISMODEGIB; WNT PROTEIN; ANILIDE;

ANTINEOPLASTIC ACTIVITY; BLOOD BRAIN BARRIER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RESISTANCE; CANCER SURGERY; CELL PROLIFERATION ASSAY; CLINICAL TRIAL (TOPIC); DRUG EFFICACY; DRUG SAFETY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MEDULLOBLASTOMA; MEDULLOBLASTOMA CELL LINE; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; NONHUMAN; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; TUMOR VOLUME; ANIMAL; ANTAGONISTS AND INHIBITORS; CEREBELLAR NEOPLASMS; METABOLISM;

ANILIDES; ANIMALS; ANTINEOPLASTIC AGENTS; CEREBELLAR NEOPLASMS; HEDGEHOG PROTEINS; HUMANS; MEDULLOBLASTOMA; PYRIDINES;

EID: 84933520362     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.2015.1052796     Document Type: Review

References (86)

1. Eberhart CG, Kepner JL, Goldthwaite PT, et al. Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 2002;94(2):552-60
2. Ries LAG SM, Gurney JG, Linet M, et al. editors. Cancer Incidence and Survival among Children and Adolescents: United States SEER Program 1975-1995. National Cancer Institute, SEER Program, NIH Pub, Bethesda, MD, USA; 1999. p. 99-4649
3. Northcott PA, Jones DT, Kool M, et al. Medulloblastomics: the end of the beginning. Nat Rev Cancer 2012;12(12): 818-34
4. Rice JS, Fischer DS. Blue rubber-bleb nevus syndrome. Generalized cavernous hemangiomatosis or venous hamartoma with medulloblastoma of the cerebellum: case report and review of the literature. Arch Dermatol 1962;86:503-11
5. Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 2007;114(2):97-109.
6. Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol 2008;65(11):1419-24
7. Rutkowski S, von Hoff K, Emser A, et al. Survival and prognostic factors of early childhood medulloblastoma: an international meta-analysis. J Clin Oncol 2010;28(33):4961-8
8. Moxon-Emre I, Bouffet E, Taylor MD, et al. Impact of craniospinal dose, boost volume, and neurologic complications on intellectual outcome in patients with medulloblastoma. J Clin Oncol 2014;32(17):1760-8
9. Piscione PJ, Bouffet E, Mabbott DJ, et al. Physical functioning in pediatric survivors of childhood posterior fossa brain tumors. Neuro Oncol 2014;16(1):147-55
10. Palmer SL, Armstrong C, Onar-Thomas A, et al. Processing speed, attention, and working memory after treatment for medulloblastoma: an international, prospective, and longitudinal study. J Clin Oncol 2013;31(28):3494-500.
11. Gajjar A, Pfister SM, Taylor MD, Gilbertson RJ. Molecular insights into pediatric brain tumors have the potential to transform therapy. Clin Cancer Res 2014;20(22):5630-40
12. Morfouace M, Shelat A, Jacus M, et al. Pemetrexed and gemcitabine as combination therapy for the treatment of Group3 medulloblastoma. Cancer Cell 2014;25(4):516-29
13. Northcott PA, Shih DJ, Peacock J, et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 2012;488(7409):49-56.
14. Taylor MD, Northcott PA, Korshunov A, et al. Molecular subgroups of medulloblastoma: the current consensus. Acta Neuropathol 2012;123(4):465-72
15. Gajjar AJ, Robinson GW. Medulloblastoma-translating discoveries from the bench to the bedside. Nat Rev Clin Oncol 2014;11(12):714-22
16. Remke M, Ramaswamy V, Taylor MD. Medulloblastoma molecular dissection: the way toward targeted therapy. Curr Opin Oncol 2013;25(6):674-81
17. Northcott PA, Korshunov A, Pfister SM, Taylor MD. The clinical implications of medulloblastoma subgroups. Nat Rev Neurol 2012;8(6):340-51
18. Kool M, Korshunov A, Remke M, et al. Molecular subgroups of medulloblastoma: an international meta-analysis of transcriptome, genetic aberrations, and clinical data of WNT, SHH, Group 3, and Group 4 medulloblastomas. Acta Neuropathol 2012;123(4):473-84
19. Markant SL, Esparza LA, Sun J, et al. Targeting sonic hedgehog-associated medulloblastoma through inhibition of Aurora and Polo-like kinases. Cancer Res 2013;73(20):6310-22
20. Robinson G, Parker M, Kranenburg TA, et al. Novel mutations target distinct subgroups of medulloblastoma. Nature 2012;488(7409):43-8
21. Heussler HS, Suri M. Sonic hedgehog. Mol Pathol 2003;56(3):129-31
22. Wang X, Venugopal C, Manoranjan B, et al. Sonic hedgehog regulates Bmi1 in human medulloblastoma brain tumor-initiating cells. Oncogene 2012;31(2):187-99
23. Manoranjan B, Venugopal C, McFarlane N, et al. Medulloblastoma stem cells: where development and cancer cross pathways. Pediatric Res 2012;71(4 Pt 2):516-22
24. Ruiz i Altaba A, Palma V, Dahmane N. Hedgehog-Gli signalling and the growth of the brain. Nat Rev Neurosci 2002;3(1):24-33
25. Teglund S, Toftgard R. Hedgehog beyond medulloblastoma and basal cell carcinoma. Biochim Biophys Acta 2010;1805(2):181-208
26. Varjosalo M, Taipale J. Hedgehog: functions and mechanisms. Genes Dev 2008;22(18):2454-72
27. Hooper JE, Scott MP. Communicating with Hedgehogs. Nat Rev Mol Cell Biol 2005;6(4):306-17
28. Sahebjam S, Siu LL, Razak AA. The utility of hedgehog signaling pathway inhibition for cancer. Oncologist 2012;17(8):1090-9
29. Hahn H, Wojnowski L, Zimmer AM, et al. Rhabdomyosarcomas and radiation hypersensitivity in a mouse model of Gorlin syndrome. Nat Med 1998;4(5):619-22
30. Xie J, Bartels CM, Barton SW, Gu D. Targeting hedgehog signaling in cancer: research and clinical developments. OncoTargets Therapy 2013;6:1425-35
31. Ellison DW, Clifford SC, Gajjar A, Gilbertson RJ. What's new in neurooncology? Recent advances in medulloblastoma. Europ J Paediat Neurol 2003;7(2):53-66
32. Reifenberger J, Wolter M, Weber RG, et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res 1998;58(9):1798-803
33. Taylor MD, Liu L, Raffel C, et al. Mutations in SUFU predispose to medulloblastoma. Nat Genet 2002;31(3):306-10
34. Gorlin RJ. Nevoid basal cell carcinoma syndrome. Dermatol Clin 1995;13(1):113-25.
35. Smith MJ, Beetz C, Williams SG, et al. Germline mutations in SUFU cause Gorlin syndrome-associated childhood medulloblastoma and redefine the risk associated with PTCH1 mutations. J Clin Oncol 2014;32(36):4155-61
36. Brugieres L, Remenieras A, Pierron G, et al. High frequency of germline SUFU mutations in children with desmoplastic/nodular medulloblastoma younger than 3 years of age. J Clin Oncol 2012;30(17):2087-93
37. Shih DJ, Northcott PA, Remke M, et al. Cytogenetic prognostication within medulloblastoma subgroups. J Clin Oncol 2014;32(9):886-96
38. Faria CC, Golbourn BJ, Dubuc AM, et al. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. Cancer Res 2015;75(1):134-46
39. Tang Y, Gholamin S, Schubert S, et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nat Med 2014;20(7):732-40
40. Chen JK, Taipale J, Cooper MK, Beachy PA. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev 2002;16(21):2743-8
41. Taipale J, Chen JK, Cooper MK, et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 2000;406(6799):1005-9
42. Berman DM, Karhadkar SS, Hallahan AR, et al. Medulloblastoma growth inhibition by hedgehog pathway blockade. Science 2002;297(5586):1559-61.
43. Tremblay MR, Lescarbeau A, Grogan MJ, et al. Discovery of a potent and orally active hedgehog pathway antagonist (IPI-926). J Med Chem 2009;52(14):4400-18
44. Jimeno A, Weiss GJ, Miller WH Jr, et al. Phase I study of the Hedgehog pathway inhibitor IPI-926 in adult patients with solid tumors. Clin Cancer Res 2013;19(10):2766-74
45. Campbell VT, Nadesan P, Ali SA, et al. Hedgehog pathway inhibition in chondrosarcoma using the smoothened inhibitor IPI-926 directly inhibits sarcoma cell growth. Mol Cancer Ther 2014;13(5):1259-69
46. Lee MJ, Hatton BA, Villavicencio EH, et al. Hedgehog pathway inhibitor saridegib (IPI-926) increases lifespan in a mouse medulloblastoma model. Proc Natl Acad Sci U S A 2012;109(20):7859-64
47. Sekulic A, Migden MR, Oro AE, et al. Efficacy and safety of vismodegib in advanced basal-cell carcinoma. Eng J Med 2012;366(23):2171-9.
48. Berlin J, Bendell JC, Hart LL, et al. A randomized phase II trial of vismodegib versus placebo with FOLFOX or FOLFIRI and bevacizumab in patients with previously untreated metastatic colorectal cancer. Clin Cancer Res 2013;19(1):258-67
49. Kim EJ, Sahai V, Abel EV, et al. Pilot clinical trial of hedgehog pathway inhibitor GDC-0449 (vismodegib) in combination with gemcitabine in patients with metastatic pancreatic adenocarcinoma. Clin Cancer Res 2014;20(23):5937-45
50. Rudin CM, Hann CL, Laterra J, et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. Eng J Med 2009;361(12):1173-8
51. Gajjar A, Stewart CF, Ellison DW, et al. Phase I study of vismodegib in children with recurrent or refractory medulloblastoma: a pediatric brain tumor consortium study. Clin Cancer Res 2013;19(22):6305-12
52. A clinical and molecular risk-directed therapy for newly diagnosed medulloblastoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01878617
53. Pan S, Wu X, Jiang J, et al. Discovery of NVP-LDE225, a potent and selective smoothened antagonist. ACS Med Chem Lett 2010;1(3):130-4
54. Buonamici S, Williams J, Morrissey M, et al. Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma. Sci Transl Med 2010;2(51):51ra70
55. D'Amato C, Rosa R, Marciano R, et al. Inhibition of Hedgehog signalling by NVP-LDE225 (Erismodegib) interferes with growth and invasion of human renal cell carcinoma cells. Br J Cancer 2014;111(6):1168-79
56. Ishii T, Shimizu Y, Nakashima K, et al. Inhibition mechanism exploration of investigational drug TAK-441 as inhibitor against Vismodegib-resistant Smoothened mutant. Eur J Pharmacol 2014;723:305-13
57. Goldman J, Eckhardt SG, Borad MJ, et al. Phase I Dose-escalation trial of the oral investigational hedgehog signaling pathway inhibitor TAK-441 in patients with advanced solid tumors. Clin Cancer Res 2015;21(5):1002-9
58. Wagner AJ, Messersmith WA, Shaik MN, et al. A Phase I Study of PF-04449913, an oral hedgehog inhibitor, in patients with advanced solid tumors. Clin Cancer Res 2015;21(5):1044-51
59. Lin TL, Matsui W. Hedgehog pathway as a drug target: Smoothened inhibitors in development. Onco Targets Ther 2012;5:47-58
60. Ibuki N, Ghaffari M, Pandey M, et al. TAK-441, a novel investigational smoothened antagonist, delays castration-resistant progression in prostate cancer by disrupting paracrine hedgehog signaling. Int J Cancer 2013;133(8):1955-66
61. Siu LLKP, Alberts SR, Kirchoff-Ross R, et al. A first-in-human, phase I study of an oral hedgehog (HH) pathway antagonist, BMS-833923 (XL139), in subjects with advanced or metastatic solid tumors. In: ASCO Annual Meeting. Journal od Clinical Oncology; 2010
62. Steven B, Gendreau DH, Ching Ping Ho, et al. Preclinical characterization of BMS 833923 (XL139), a hedgehog (HH) pathway inhibitor in early clinical development. In: AACR-NCI-EORTC International Conference. Molecular Cancer Therapeutics, Boston, MA; 2009
63. Kimura H, Ng JM, Curran T. Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 2008;13(3):249-60
64. Kool M, Jones DT, Jager N, et al. Genome sequencing of SHH medulloblastoma predicts genotype-related response to smoothened inhibition. Cancer Cell 2014;25(3):393-405
65. Meani RE, Lim SW, Chang AL, Kelly JW. Emergence of chemoresistance in a metastatic basal cell carcinoma patient after complete response to hedgehog pathway inhibitor vismodegib (GDC-0449). Australas J Dermatol 2014;55(3):218-21
66. Yauch RL, Dijkgraaf GJ, Alicke B, et al. Smoothened mutation confers resistance to a Hedgehog pathway inhibitor in medulloblastoma. Science 2009;326(5952):572-4
67. Kim J, Lee JJ, Kim J, et al. Arsenic antagonizes the Hedgehog pathway by preventing ciliary accumulation and reducing stability of the Gli2 transcriptional effector. Proc Nat Acad Sci USA 2010;107(30):13432-7
68. Kim J, Aftab BT, Tang JY, et al. Itraconazole and arsenic trioxide inhibit Hedgehog pathway activation and tumor growth associated with acquired resistance to smoothened antagonists. Cancer Cell 2013;23(1):23-34
69. Larsen AR, Bai RY, Chung JH, et al. Repurposing the antihelmintic mebendazole as a hedgehog inhibitor. Mol Cancer Ther 2015;14(1):3-13
70. Bai RY, Staedtke V, Rudin CM, et al. Effective treatment of diverse medulloblastoma models with mebendazole and its impact on tumor angiogenesis. Neuro Oncol 2015;17(4):545-54
71. Bladt F, Riethmacher D, Isenmann S, et al. Essential role for the c-met receptor in the migration of myogenic precursor cells into the limb bud. Nature 1995;376(6543):768-71
72. Ieraci A, Forni PE, Ponzetto C. Viable hypomorphic signaling mutant of the Met receptor reveals a role for hepatocyte growth factor in postnatal cerebellar development. Proc Natl Acad Sci U S A 2002;99(23):15200-5
73. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012;12(2):89-103
74. Li Y, Lal B, Kwon S, et al. The scatter factor/hepatocyte growth factor: c-met pathway in human embryonal central nervous system tumor malignancy. Cancer Res 2005;65(20):9355-62
75. Kongkham PN, Onvani S, Smith CA, Rutka JT. Inhibition of the MET Receptor Tyrosine Kinase as a Novel Therapeutic Strategy in Medulloblastoma. Trans Oncol 2010;3(6):336-43
76. Faria CC, Golbourn BJ, Dubuc AM, et al. Foretinib is effective therapy for metastatic sonic hedgehog medulloblastoma. Cancer Res 2015;75(1):134-46
77. Vismodegib in treating younger patients with recurrent or refractory medulloblastoma. Available from: https://clinicaltrials.gov/ct2/show/NCT01239316
78. Study of Vismodegib in combination with temozolomide versus temozolomide alone in patients with medulloblastomas with an activation of the sonic hedgehog pathway. Available from: https://clinicaltrials.gov/ct2/show/NCT01601184
79. GDC-0449 in Treating young patients with medulloblastoma that is recurrent or did not respond to previous treatment. Available from: https://clinicaltrials.gov/ct2/show/NCT00822458
80. Vismodegib in Treating patients with recurrent or refractory medulloblastoma. Available from: https://clinicaltrials.gov/ct2/show/NCT00939484
81. A Phase II study of oral LDE225 in patients with hedge-hog (Hh)-pathway activated relapsed medulloblastoma (MB). Available from: https://clinicaltrials.gov/ct2/show/NCT01708174
82. A phase i dose finding and safety study of oral lde225 in children and a phase ii portion to assess preliminary efficacy in recurrent or refractory MB. Available from: https://clinicaltrials.gov/ct2/show/NCT01125800
83. Dose Finding and safety of oral LDE225 in patients with advanced solid tumors. Available from: https://clinicaltrials.gov/ct2/show/NCT00880308
84. An East Asian Study of LDE225. Available from: https://clinicaltrials.gov/ct2/show/NCT01208831
85. A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT00761696
86. A Study of TAK-441 in Adult Patients With Advanced Nonhematologic Malignancies. Available from: https://clinicaltrials.gov/ct2/show/NCT01204073